Table 2. Efficacy of daclatasvir and asunaprevir in hepatitis C.
| Study | Viral genotype |
Treatment regimen (24 weeks) |
Sustained virological response‡ | ||
|---|---|---|---|---|---|
| Treatment-naïve patients | Treatment-experienced patient | Intolerant/ ineligible patients | |||
| Manns5 | 1b | daclatasvir + asunaprevir | 90% (182/203) | 82% (168/205) | 82% (192/235) |
| Kumada6 | - | 80% (70/87) | 88% (119/135) | ||
| Jensen7 | 1 | daclatasvir + asunaprevir + peginterferon + ribavirin | - | Overall 93% (329/354) |
- |
| Patients with cirrhosis 90% (66/73) | |||||
| 4 | - | Overall 98% (43/44) |
- | ||
| Patients with cirrhosis 95% (19/20) | |||||
‡ Defined as proportion of patients with viral RNA less than the lower limit of quantification in serum measured 12 weeks after the end of treatment.